1638338-43-8
1638338-43-8
Chemical Structure
Navicixizumab
Synonym(s): OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)
- No. CAS: 1638338-43-8
- Formula:N/A
- Molecular Weight:(145.83 kDa)
SMILES: [Navicixizumab]
Biological Activity: Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Navicixizumab | 99.83% | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. [Content Brief]
- [2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. [Content Brief]
- [3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.
